Cannae Holdings, Inc. Announces Increase in Share Repurchase Authorization, Expanding its Commitment to Returning Capital to Shareholders
~ Cannae Increases Share Buyback Authorization to 14.9 Million Shares ~ LAS VEGAS–(BUSINESS WIRE)–Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or... Read more.
Bausch + Lomb Launches R&D “Teach-in” Webinar Series
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better... Read more.
Data Management Overtakes Cost and Talent as Top AI Challenge as 65% of Enterprises Race to Build Reliable Agentic Capabilities
“Significant” investment in AI has tripled compared to the previous year and half of organizations are now committing more than 20% of their total tech budget... Read more.
TASKING Accelerates the Development and Verification of Safety- and Security-Critical AUTOSAR Compliant Systems
TASKING optimizes AUTOSAR software development workflows from requirements through verification and deployment with integration of and enhancements to its compiler... Read more.
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter... Read more.
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
– Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE-DMD to treat serious conditions like Duchenne muscular dystrophy... Read more.
KNAPP North America Establishes Executive-Led Customer Service Model for Large-Scale Automation
Promotion of Deep Tayal to Senior Vice President of Customer Service highlights KNAPP’s commitment to proactive, data-driven support and long-term customer success... Read more.
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program PRINCETON, N.J.–(BUSINESS... Read more.
Fluor Announces Appointment of Robert G. (Bob) Card to its Board of Directors
IRVING, Texas–(BUSINESS WIRE)–Fluor Corporation (NYSE: FLR) announced today that Robert G. (Bob) Card, former President and CEO of SNC‑Lavalin and... Read more.
Fluor Announces Retirement of Executive Chairman, David E. Constable, and Appointment of James T. (Jim) Hackett as Chairman of the Board
IRVING, Texas–(BUSINESS WIRE)–Fluor Corporation (NYSE: FLR) today announced that David E. Constable, Executive Chairman, will step down from the Board... Read more.